Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T14:01:32.392Z.
Calculation as of: 2026-10-06T14:01:32.392Z.
Quote observation: 2026-10-06T13:59:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c8d7801cb5d69976804150322740a3f9972799eb944d256c77d6faa31d53dc8f
PE RATIO
N/A
Market Cap
$31.23M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| EUDA Health Holdings Limited (EUDA) | $32.50M | N/A | N/A | N/A | N/A |
| MIRA Pharmaceuticals, Inc. (MIRA)vs › | $32.24M | N/A | N/A | N/A | N/A |
| Context Therapeutics Inc. (CNTX)vs › | $32.36M | N/A | N/A | N/A | N/A |
| BeyondSpring Inc. (BYSI)vs › | $31.39M | N/A | N/A | N/A | N/A |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $31.23M | N/A | N/A | N/A | N/A |
| MDxHealth S.A. (MDXH)vs › | $30.89M | N/A | N/A | N/A | N/A |
| HeartBeam, Inc. (BEAT)vs › | $33.30M | N/A | N/A | N/A | N/A |
| Aligos Therapeutics, Inc. (ALGS)vs › | $34.22M | N/A | N/A | N/A | N/A |
| CervoMed Inc. (CRVO)vs › | $29.44M | N/A | 876.90 | 876.90 | 876.90 |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.50M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
10.9
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$17.40
Forward EPS (Est.)
$1.60
Forward P/E
10.87
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute